Glaucoma, Hypertension
Conditions
Keywords
Drug consumption, The Xal-Ease device, Patient's compliance, Using a novel Pfizer-Pharmacia device to facilitate the Xalatan/Xalacom instillation and to avoid loss of eye drops
Brief summary
Xal-Ease is a novel Pfizer-Pharmacia device aimed to significantly facilitate the Xalatan/Xalacom instillation and to avoid loss of Xalatan/Xalacom eye drops due to incorrect instillation. Patients on Xalatan/Xalacom who have consumed more than one bottle per month within a year according to consumption data drawn from the Clalit Health Services database, will use the Xal-Ease device for a year. The device is expected to reduce consumption of bottles and result in saving money for both patients and medical care providers.
Interventions
DEVICEXal-Ease
Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
Sponsors
Meir Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with glaucoma or hypertension treated with Xalatan/Xalacom who have consumed more than one bottle per month within a year prior to initiation of the study.
Exclusion criteria
* Patients younger than 18 years, * Patients with severe manual disabilities, * Patients with impaired cognition and mentality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Consumption of Xalatan/Xalacom bottles per year per patient. | 12 months. |
Secondary
| Measure | Time frame |
|---|---|
| Evaluating cost of Xalatan/Xalacom eye drops use per year with Xal-Ease | 12 months |
| Characterizing the optimal conditions for proper usage of the Xal-Ease device | 12 months |
Countries
Israel
Outcome results
None listed